Skip to main content

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022

Novosanis will be attending the Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022 conference on March 1 & 2. The conference will focus on the development of liquid biopsies utilizing circulating cell-free DNA (cfDNA), circulating tumour cells (CTCs) and other biomarkers found in biofluids.

Visit our booth to learn more about our unique urine collection & stabilization device, Colli-Pee. We look forward to seeing you there!

https://selectbiosciences.com/conferences/index.aspx?conf=EXLBPEU2022

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.